Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Johnson-and-Johnson (JNJ) stocks

Learn how to easily invest in Johnson-and-Johnson stocks.

Johnson-and-Johnson is a drug manufacturers-general business based in the US. Johnson-and-Johnson stocks (JNJ.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $179.66 – an increase of 7.57% over the previous week. Johnson-and-Johnson employs 144,000 staff and has a trailing 12-month revenue of around $94.9 billion.

How to buy stocks in Johnson-and-Johnson

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – JNJ – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Johnson-and-Johnson stock price (NYSE:JNJ)

Use our graph to track the performance of JNJ stocks over time.

Johnson-and-Johnson shares at a glance

Information last updated 2022-06-21.
Latest market close$182.29
52-week range$153.87 - $185.50
50-day moving average $178.16
200-day moving average $169.89
Wall St. target price$190.21
PE ratio 22.8383
Dividend yield $4.24 (2.67%)
Earnings per share (TTM) $7.42

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$0 if conditions met, otherwise $100 a year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Scotia iTRADE
Finder Rating:
3.8 / 5
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get $25 when you open a Wealthsimple Trade account and fund at least $150.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends August 31, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Johnson-and-Johnson stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Johnson-and-Johnson price performance over time

Historical closes compared with the close of $182.29 from 2022-06-24

1 week (2022-06-17) 7.57%
1 month (2022-05-24) 0.49%
3 months (2022-03-25) 3.04%
6 months (2021-12-21) N/A
1 year (2021-06-25) 11.01%
2 years (2020-06-25) 30.51%
3 years (2019-06-25) 26.38%
5 years (2017-06-23) 33.61%

Is Johnson-and-Johnson under- or over-valued?

Valuing Johnson-and-Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson-and-Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Johnson-and-Johnson's P/E ratio

Johnson-and-Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Johnson-and-Johnson shares trade at around 23x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Johnson-and-Johnson's PEG ratio

Johnson-and-Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.3302. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson-and-Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Johnson-and-Johnson's EBITDA

Johnson-and-Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $32.4 billion.

The EBITDA is a measure of a Johnson-and-Johnson's overall financial performance and is widely used to measure a its profitability.

Johnson-and-Johnson financials

Revenue TTM $94.9 billion
Operating margin TTM 26.5%
Gross profit TTM $64 billion
Return on assets TTM 8.96%
Return on equity TTM 28.22%
Profit margin 20.9%
Book value $28.41
Market capitalisation $445.9 billion

TTM: trailing 12 months

Johnson-and-Johnson's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson-and-Johnson.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Johnson-and-Johnson's total ESG risk score

Total ESG risk: 35.8

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson-and-Johnson's overall score of 35.8 (as at 01/01/2019) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Johnson-and-Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Johnson-and-Johnson's environmental score

Environmental score: 3.79/100

Johnson-and-Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson-and-Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Johnson-and-Johnson's social score

Social score: 25.14/100

Johnson-and-Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson-and-Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Johnson-and-Johnson's governance score

Governance score: 14.87/100

Johnson-and-Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson-and-Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Johnson-and-Johnson's controversy score

Controversy score: 4/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Johnson-and-Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson-and-Johnson has a damaged public profile.

Johnson-and-Johnson share dividends


Dividend payout ratio: 43.62% of net profits

Recently Johnson-and-Johnson has paid out, on average, around 43.62% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.67% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson-and-Johnson shareholders could enjoy a 2.67% return on their shares, in the form of dividend payments. In Johnson-and-Johnson's case, that would currently equate to about $4.24 per share.

While Johnson-and-Johnson's payout ratio might seem fairly standard, it's worth remembering that Johnson-and-Johnson may be investing much of the rest of its net profits in future growth.

Johnson-and-Johnson's most recent dividend payout was on 7 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 23 May 2022 (the "ex-dividend date").

Have Johnson-and-Johnson's shares ever split?

Johnson-and-Johnson's shares were split on a 2:1 basis on 13 June 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson-and-Johnson shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Johnson-and-Johnson shares which in turn could have impacted Johnson-and-Johnson's share price.

Johnson-and-Johnson share price volatility

Over the last 12 months, Johnson-and-Johnson's shares have ranged in value from as little as $153.8672 up to $185.498. A popular way to gauge a stock's volatility is its "beta".

JNJ.US volatility(beta: 0.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson-and-Johnson's is 0.6583. This would suggest that Johnson-and-Johnson's shares are less volatile than average (for this exchange).

Johnson-and-Johnson overview

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o. b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site